Receptos, Inc.

Receptos Announces License to Advance Structure-Based Drug Discovery for High-Value G-Protein Coupled Receptor (GPCR) Targets

Receptos Announces License to Advance Structure-Based Drug Discovery for High-Value G-Protein Coupled Receptor (GPCR) Targets

January 6, 2011

Deal with Ortho-McNeil-Janssen Pharmaceuticals, Inc. represents blueprint for technology sharing as a new paradigm emerges from Receptos for discovering best-in-class therapeutic drug candidates for GPCR targets

Receptos, Inc.

Receptos Announces Exclusive Collaboration with Lilly

Receptos Announces Exclusive Collaboration with Lilly

January 6, 2011

Collaborative efforts to focus on structure determination and lead generation for high-value G-protein Coupled Receptor (GPCR) target

Eleven Biotherapeutics, Inc.

Eleven Biotherapeutics Appoints Eric Furfine, Ph.D., to President of Research and Development

Eleven Biotherapeutics Appoints Eric Furfine, Ph.D., to President of Research and Development

January 6, 2011

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, today announced the appointment of Eric Furfine, Ph.D., as president of research and development. Dr. Furfine replaces Burt Adelman, M.D., who has served as the company’s interim president of research and development since its founding. Dr. Adelman will continue to serve as a scientific advisor to the company.

BG Medicine, Inc.

BG Medicine announces new publication on prognostic value of galectin-3 in heart failure patients

BG Medicine announces new publication on prognostic value of galectin-3 in heart failure patients

January 4, 2011

January 4, 2011 -- Waltham, MA, BG Medicine, a life sciences company focused on the discovery, development and commercialization of novel diagnostics, today announced the publication* of a study exploring the predictive value of plasma galectin-3 levels in heart failure (HF) patients with reduced and preserved ejection fraction.

Adnexus Therapeutics

Former Portfolio Company Adnexus Therapeutics CEO, John Mendlein, Profiled by Xconomy.com as "Parallel Entrepreneur"

Former Portfolio Company Adnexus Therapeutics CEO, John Mendlein, Profiled by Xconomy.com as "Parallel Entrepreneur"

January 3, 2011

John Mendlein, former CEO of Flagship portfolio company Adnexus Therapeutics, was highlighted recently on Xconomy.com. Mendlein successfully led Adnexus to a $500M exit with its sale to Bristol-Myers Squibb in September of 2007.

John Mendlein, Biotech Exec With Surfer Look, Follows Winding Path as “Parallel Entrepreneur”

Luke Timmerman 1/3/11, Xconomy.com

LS9

LS9 Raises $30 Million to Ready Products for Commercial Production

LS9 Raises $30 Million to Ready Products for Commercial Production

December 21, 2010

Series D Round Led by BlackRock with Participation by All Previous Investors

Moderna

Flagship VentureLabs Company ModeRNA Therapeutics, and co-founder, Derrick Rossi, both Cited by Time Magazine for Significant Advances and Contributions in 2010

Flagship VentureLabs Company ModeRNA Therapeutics, and co-founder, Derrick Rossi, both Cited by Time Magazine for Significant Advances and Contributions in 2010

December 9, 2010

In it's annual wrap-up of people and events that mattered, Time Magazine this year recognized the work behind ModeRNA Therapeutics:

"Working with the groundbreaking type of stem cell known as induced pluripotent stem (iPS) cells — which can be generated from a skin cell, completely bypassing the need for embryos — researchers at Children's Hospital Boston have overcome a critical hurdle in making the technology safe for human patients."

LS9

LS9, Inc. Appoints Ed Dineen Chief Executive Officer

LS9, Inc. Appoints Ed Dineen Chief Executive Officer

December 8, 2010

SOUTH SAN FRANCISCO, CA - December 8, 2010 - Biotechnology company LS9, Inc. today announced the appointment of Edward J. Dineen as Chief Executive Officer and President. Mr. Dineen will also become a member of the LS9 Board of Directors. He replaces Bill Haywood who has served as CEO of LS9 since September 2008.

Ze-gen, Inc.

Walt Howard Joins Ze-gen As Chief Executive Officer

Walt Howard Joins Ze-gen As Chief Executive Officer

December 8, 2010

 Boston, MA — December 8, 2010 — Ze-gen, Inc., a leading developer and integrator of advanced gasification technology to convert waste streams into synthesis gas, welcomes Walter Howard as Chief Executive Officer, replacing Bill Davis who founded Ze-gen in 2004. An industry veteran, with more than 30 years of global power project development experience, Mr. Howard has held CEO, COO, CFO, and SVP executive positions with utility leaders including General Electric, American Water, US Generating (an affiliate of PG&E and Bechtel), Noble Power Assets, J.Makowski Co.

Receptos, Inc.

Faheem Hasnain Named President and Chief Executive Officer of Receptos

Faheem Hasnain Named President and Chief Executive Officer of Receptos

December 2, 2010

Industry veteran will strengthen Receptos’s clinical and commercial expertise in multiple sclerosis and expand activities including the potential to acquire additional focused therapeutic assets